Esomeprazole + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Chronic Posterior Laryngitis (CPL)
Conditions
Chronic Posterior Laryngitis (CPL)
Trial Timeline
Feb 1, 2002 → Mar 1, 2003
NCT ID
NCT00628667About Esomeprazole + Placebo
Esomeprazole + Placebo is a approved stage product being developed by AstraZeneca for Chronic Posterior Laryngitis (CPL). The current trial status is completed. This product is registered under clinical trial identifier NCT00628667. Target conditions include Chronic Posterior Laryngitis (CPL).
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01069939 | Phase 3 | Completed |
| NCT00660660 | Approved | Completed |
| NCT00542789 | Phase 3 | Completed |
| NCT00287339 | Approved | Completed |
| NCT00745849 | Pre-clinical | Completed |
| NCT00628953 | Phase 2 | Completed |
| NCT00628667 | Approved | Completed |
Competing Products
20 competing products in Chronic Posterior Laryngitis (CPL)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| macitentan 10 mg | BML, Inc. | Phase 3 | 76 |
| KPL-716 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 38 |
| Fludarabine + Cyclophosphamide + PRGN-3007 | Precigen | Phase 1 | 28 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 52 |
| THB001 | Third Harmonic Bio | Phase 1 | 25 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 2 | 44 |
| Empagliflozin + Matching placebo | Eli Lilly | Phase 3 | 77 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Venetoclax + Rituximab | Eli Lilly | Phase 3 | 77 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 52 |
| Pirtobrutinib | Eli Lilly | Phase 2 | 52 |
| Ibrutinib + LY3214996 | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Acalabrutinib | Eli Lilly | Phase 2 | 52 |
| LYR-210 | Lyra Therapeutics | Phase 2 | 44 |
| LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2) | Lyra Therapeutics | Phase 2 | 44 |
| 480 Mometasone Furoate Sinus Drug Depot | Lyra Therapeutics | Phase 1 | 25 |
| LYR-210 + Sham procedure control | Lyra Therapeutics | Phase 3 | 69 |